window.dataLayer = window.dataLayer || []; (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5L46PPF2');

PAAM Hybrid 2023

Back
02 - 04 November 2023 Porto, Portugal

OAS2 – Drug and Skin Allergy

Friday 03 Nov, 10:30 AM - 12:00 PM Porto/Portugal (CET -1)
Porto Hall Oral Abstract Session
Abstract Text
10:30
Drug provocation test to acetyl salicylic acid in a children cohort
Abstract Text
10:42
Omalizumab as an off-label prescription for pediatric patients
Abstract Text
10:54
Long-Term Dupilumab Treatment is Not Associated With an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis in an Open-Label Extension Study
Abstract Text
11:06
Drug Hypersensitivity Reactions In A Pediatric Population Before And After COVID-19 Pandemic - A Retrospective Study In A Portuguese Hospital Center
Abstract Text
11:18
Safety of cefixime use in penicillin allergic pediatric patients - a review spanning from 2010 to 2023 at a tertiary hospital
Abstract Text
11:30
Low fecal butyrate levels at the age of one year is associated with an increased risk of atopic dermatitis in early childhood
Abstract Text
11:42
Drug provocation tests with beta-lactam – from suspicion to confirmation

Chairs

Speakers